"We have a successful track record of addressing serious medical conditions."

Antony Loebel, M.D.
Executive Vice President, Chief Medical Officer, Head of Global Clinical Development

Antony Loebel, M.D.

Executive Vice President, Chief Medical Officer, Head of Global Clinical Development

Dr. Tony Loebel is Executive Vice President and Chief Medical Officer at Sunovion Pharmaceuticals Inc. He also serves as Head of Global Clinical Development for Sunovion and its parent company Sumitomo Dainippon Pharma Co., Ltd.

Dr. Loebel is a board-certified psychiatrist and scientist who joined Sunovion in 2007. He is a member of the Sunovion Executive Leadership Team and Board of Directors, as well as an Executive Officer of Sumitomo Dainippon Pharma in Japan. Dr. Loebel provides strategic direction and leadership of Sunovion R&D, with responsibility for global drug development. In addition Dr. Loebel provides medical oversight of all investigational drugs and marketed products. Dr. Loebel led the global development of Latuda® (lurasidone HCl), the company's flagship product that is approved for the treatment of patients with schizophrenia and bipolar depression. He was also responsible for the development and FDA approval of Aptiom® (eslicarbazepine acetate) as monotherapy or adjunctive therapy for patients with partial-onset seizures.

For his achievements in advancing new treatments for central nervous system disorders, the International Society for CNS Drug Development (ISCDD) presented Dr. Loebel with its 2015 Award for Leadership. Selected by PharmaVoice in 2013 as one of the "100 Most Inspiring People" in the pharmaceutical industry, Dr. Loebel is widely recognized by his peers as an innovative leader guided by his dedication to patients. Dr. Loebel has published more than 120 peer-reviewed scientific papers and approximately 600 abstracts and posters. He holds editorial positions at distinguished publications including CNS Spectrums, BMC Psychiatry and Schizophrenia Research. He is a Clinical Assistant Professor of Psychiatry at the New York University School of Medicine. Dr. Loebel serves on the Pharmaceutical Research and Manufacturers of America (PhRMA) BioMedical Advisory Council and on the Massachusetts Biotechnology Council (MassBio) Board of Directors. Dr. Loebel is a Fellow of the American Psychiatric Association and a member of the American College of Neuropsychopharmacology (ACNP).

Dr. Loebel earned a M.D. from the University of Washington School of Medicine in Seattle. He completed his residency in Psychiatry and a research fellowship in Clinical Neurosciences at Zucker Hillside Hospital (Northwell Health) in Glen Oaks, New York. Dr. Loebel holds a Bachelor of Arts degree with Majors in Zoology and English from the University of Washington.